Seres therapeutics reports first quarter 2025 financial results and provides business updates

In line with recent fda feedback, seres expects to submit a phase 2 study protocol to fda in the coming weeks for ser-155 for the prevention of bloodstream infections (bsis) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-hsct) for the treatment of hematological malignancies ser-155 phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in bsis, and support broader potential for seres' live biotherapeutics to address inflammatory and immune diseases seres advancing ser-155 strategic partnership discussions in support of further development in allo-hsct and potential expansion into other target populations conference call at 8:30 a.m. et today cambridge, mass.
mcrb Ratings Summary
mcrb Quant Ranking